Date:5/15/2012

s508300NON-CURRENT LIABILITIES:Derivative related to service agreement 3,5531,436Total non-current liabilities3,5531,436SHAREHOLDERS' EQUITY:Share capital Preferred Shares -Authorized: 1,000,000 shares at March 31, 2012 and December 31, 2011;
Issued and Outstanding: 0 shares at March 31, 2012 and December 31,
2011 --Common Shares of  $0.001 par value -Authorized: 100,000,000 shares at March 31, 2012 and December 31,
2011; Issued and Outstanding: 46,985,517 shares at March 31, 2012 and
December 31, 20114747Additional Paid-in capital4,6824,614Accumulated other comprehensive loss(161)(44)Accumulated deficit(4,225)(1,401)Total shareholders' equity3433,216Total liabilities and shareholders' equity$
4,404$
4,952This release contains forward-looking statements regarding OphthaliX's future plans and expected performance based on assumptions the Company believes to be reasonable.  A number of risks and uncertainties could cause actual results to differ materially from these statements, including, without limitation, the success rate of business development efforts and the timeliness of development activities, and other risk factors described from time to time in the Company's reports filed with the SEC.  In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond the Company's control. OphthaliX Inc. undertakes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

'/>"/>

SOURCE OphthaliX Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results